Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
57
SLGL Quote, Financials, Valuation and Earnings
Last price:
$42.15
Seasonality move
:
0.01%
Day range:
$38.30 - $44.43
52-week range:
$4.02 - $52.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.73x
P/B ratio:
4.18x
Volume:
12.1K
Avg. volume:
18.4K
1-year change:
680.36%
Market cap:
$108.7M
Revenue:
$11.5M
EPS (TTM):
-$3.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
$300K | -$2.09 | 2238.13% | -15854.2% | $50.00 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
$39.01 | $50.00 | $108.7M | -- | $0.00 | 0% | 5.73x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.28 | $2.50 | $4.5M | -- | $0.00 | 0% | 1.58x |
|
CGEN
Compugen Ltd.
|
$1.53 | $6.25 | $143.1M | 55.83x | $0.00 | 0% | 20.44x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.28 | $399.00 | $3.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
3.99% | 0.149 | 1.33% | 4.99x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
-- | -$6.3M | -30.42% | -31.72% | -1572% | -$7.6M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Sol-Gel Technologies Ltd. vs. Competitors
-
Which has Higher Returns SLGL or CANF?
Can-Fite BioPharma Ltd. has a net margin of -1485.5% compared to Sol-Gel Technologies Ltd.'s net margin of --. Sol-Gel Technologies Ltd.'s return on equity of -31.72% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$2.13 $27.1M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About SLGL or CANF?
Sol-Gel Technologies Ltd. has a consensus price target of $50.00, signalling upside risk potential of 28.17%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 784.02%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is SLGL or CANF More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.355, which suggesting that the stock is 35.494% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock SLGL or CANF?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or CANF?
Sol-Gel Technologies Ltd. quarterly revenues are $400K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Sol-Gel Technologies Ltd.'s net income of -$5.9M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 5.73x versus 1.58x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.5.73x -- $400K -$5.9M CANFCan-Fite BioPharma Ltd.1.58x -- -- --
-
Which has Higher Returns SLGL or CGEN?
Compugen Ltd. has a net margin of -1485.5% compared to Sol-Gel Technologies Ltd.'s net margin of -369.06%. Sol-Gel Technologies Ltd.'s return on equity of -31.72% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$2.13 $27.1M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About SLGL or CGEN?
Sol-Gel Technologies Ltd. has a consensus price target of $50.00, signalling upside risk potential of 28.17%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 308.5%. Given that Compugen Ltd. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe Compugen Ltd. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.0 0 0 CGENCompugen Ltd.4 0 0 -
Is SLGL or CGEN More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.355, which suggesting that the stock is 35.494% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock SLGL or CGEN?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or CGEN?
Sol-Gel Technologies Ltd. quarterly revenues are $400K, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Sol-Gel Technologies Ltd.'s net income of -$5.9M is higher than Compugen Ltd.'s net income of -$7M. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 5.73x versus 20.44x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.5.73x -- $400K -$5.9M CGENCompugen Ltd.20.44x 55.83x $1.9M -$7M
-
Which has Higher Returns SLGL or NSRX?
Nasus Pharma has a net margin of -1485.5% compared to Sol-Gel Technologies Ltd.'s net margin of --. Sol-Gel Technologies Ltd.'s return on equity of -31.72% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$2.13 $27.1M NSRXNasus Pharma-- -- -- -
What do Analysts Say About SLGL or NSRX?
Sol-Gel Technologies Ltd. has a consensus price target of $50.00, signalling upside risk potential of 28.17%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Sol-Gel Technologies Ltd. has higher upside potential than Nasus Pharma, analysts believe Sol-Gel Technologies Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.0 0 0 NSRXNasus Pharma0 0 0 -
Is SLGL or NSRX More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.355, which suggesting that the stock is 35.494% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLGL or NSRX?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or NSRX?
Sol-Gel Technologies Ltd. quarterly revenues are $400K, which are larger than Nasus Pharma quarterly revenues of --. Sol-Gel Technologies Ltd.'s net income of -$5.9M is higher than Nasus Pharma's net income of --. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 5.73x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.5.73x -- $400K -$5.9M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns SLGL or PHGE?
BiomX, Inc. has a net margin of -1485.5% compared to Sol-Gel Technologies Ltd.'s net margin of --. Sol-Gel Technologies Ltd.'s return on equity of -31.72% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$2.13 $27.1M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About SLGL or PHGE?
Sol-Gel Technologies Ltd. has a consensus price target of $50.00, signalling upside risk potential of 28.17%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 17400%. Given that BiomX, Inc. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe BiomX, Inc. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is SLGL or PHGE More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.355, which suggesting that the stock is 35.494% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock SLGL or PHGE?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or PHGE?
Sol-Gel Technologies Ltd. quarterly revenues are $400K, which are larger than BiomX, Inc. quarterly revenues of --. Sol-Gel Technologies Ltd.'s net income of -$5.9M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 5.73x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.5.73x -- $400K -$5.9M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
